Stock 300558 BETTA PHARMACEUTICALS CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Betta Pharmaceuticals Co., Ltd. Stock

Equities

300558

CNE100002DD9

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-04-24 pm EDT 		5-day change 1st Jan Change
39.11 CNY +0.03% Intraday chart for Betta Pharmaceuticals Co., Ltd. +5.82% -24.13%
Apr. 19 Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Jan. 04 C4 Therapeutics, Inc. announced that it has received $24.999997 million in funding from Betta Pharmaceuticals Co., Ltd. CI

Financials

Sales 2024 * 3.4B 469M Sales 2025 * 4.26B 589M Capitalization 16.36B 2.26B
Net income 2024 * 600M 82.8M Net income 2025 * 634M 87.49M EV / Sales 2024 * 5.39 x
Net Debt 2024 * 1.97B 272M Net Debt 2025 * 1.47B 203M EV / Sales 2025 * 4.18 x
P/E ratio 2024 *
27.3 x
P/E ratio 2025 *
25.8 x
Employees 1,961
Yield 2024 *
0.5%
Yield 2025 *
0.58%
Free-Float 51.55%
More Fundamentals * Assessed data

Chart Betta Pharmaceuticals Co., Ltd.

Dynamic Chart

Latest news about Betta Pharmaceuticals Co., Ltd.

Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
C4 Therapeutics, Inc. announced that it has received $24.999997 million in funding from Betta Pharmaceuticals Co., Ltd. CI
Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Beijing Mabworks Biotech Co., Ltd. announced that it expects to receive CNY 150.000042 million in funding from Betta Pharmaceuticals Co., Ltd. CI
C4 Therapeutics Shares Up 18% After Lung Cancer Drug Application Receives FDA Clearance DJ
Betta Pharmaceuticals Gets Nod for Voronib Tablets' Listing MT
Betta Pharmaceuticals Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2022, Payable on 15 June 2023 CI
C4 Therapeutics, Betta Pharmaceuticals Sign Deal to Develop, Commercialize CFT8919 in Greater China MT
C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC Degrader of EGFR L858R for NSCLC CI
C4 Therapeutics, Inc. announced that it expects to receive $24.999997 million in funding from Betta Pharmaceuticals Co., Ltd. CI
Betta Pharmaceuticals Co., Ltd. Approves Cash Dividend for the Year of 2022 CI
Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Betta Pharmaceuticals Co., Ltd. Announces Profit Distribution Proposal for 2022 CI
Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
More news

Quotes and Performance

1 day+1.16%
1 week+5.79%
Current month-4.45%
1 month-11.82%
3 months-6.01%
6 months-28.34%
Current year-24.15%
More quotes

Highs and lows

1 week
35.58
Extreme 35.58
39.18
1 month
35.58
Extreme 35.58
43.70
Current year
33.11
Extreme 33.11
52.33
1 year
33.11
Extreme 33.11
73.11
3 years
33.11
Extreme 33.11
122.00
5 years
33.11
Extreme 33.11
160.66
10 years
23.19
Extreme 23.19
160.66
More quotes

Managers and Directors - Betta Pharmaceuticals Co., Ltd.

Managers TitleAgeSince
Jia Tong CEO
 Chief Executive Officer 46 02-12-31
Lie Ming Ding CEO
 Chief Executive Officer 60 03-01-06
Jian Xun Fan DFI
 Director of Finance/CFO 53 15-12-31
Members of the board TitleAgeSince
Lie Ming Ding CEO
 Chief Executive Officer 60 03-01-06
Jiang Nan Cai BRD
 Director/Board Member 67 19-11-21
Jia Bing Wang CTO
 Chief Tech/Sci/R&D Officer 60 16-02-27
More insiders

ETFs positioned on Betta Pharmaceuticals Co., Ltd.

Name Weight AuM 1st Jan change Investor Rating
KRANESHARES MSCI ALL CHINA HEALTH CARE INDEX UCITS ETF - USD ETF KraneShares MSCI All China Health Care Index UCITS ETF - USD
0.36% 2 M€ -19.10% -
More ETFs positioned on Betta Pharmaceuticals Co., Ltd.

Quotes

Date Price Change Volume
24-04-24 39.11 +0.03% 6 718 199
24-04-24 39.1 +1.16% 7,371,825
24-04-23 38.65 +0.91% 9,784,535
24-04-22 38.3 +6.27% 11,707,330
24-04-19 36.04 -1.02% 4,751,895

End-of-day quote Shenzhen S.E., April 23, 2024

More quotes

Company Profile

Betta Pharmaceuticals Co Ltd is a company mainly engaged in research, development, production and sales of innovative drugs for the treatment of malignant tumors. The Company's primary product is its self-developed icotinib hydrochloride (Conmana), a small molecule targeted anticancer drug used for the treatment of lung cancer. The Company is also engaged in promotional services, real estate leasing and other businesses.
Sector
Pharmaceuticals
Calendar
2024-05-15 - Annual General Meeting
More about the company

Income Statement Evolution

More financial data

Ratings for Betta Pharmaceuticals Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
39.1 CNY
Average target price
54.14 CNY
Spread / Average Target
+38.45%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

1st Jan change Capi.
BETTA PHARMACEUTICALS CO., LTD. Stock Betta Pharmaceuticals Co., Ltd.
-24.15% 2.26B
MERCK KGAA Stock Merck KGaA
+5.73% 70.78B
KYOWA KIRIN CO. LTD. Stock Kyowa Kirin Co. Ltd.
+11.16% 9.15B
SK BIOPHARMACEUTICALS CO., LTD. Stock SK Biopharmaceuticals Co., Ltd.
-15.34% 4.84B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD. Stock Shenyang Xingqi Pharmaceutical Co.,Ltd.
+34.54% 4.22B
YUHAN CORPORATION Stock Yuhan Corporation
+5.09% 3.92B
INDIVIOR PLC Stock Indivior PLC
+27.76% 2.55B
CHANGCHUN BCHT BIOTECHNOLOGY CO. Stock Changchun BCHT Biotechnology Co.
-28.33% 2.24B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. Stock Shanghai Shyndec Pharmaceutical Co., Ltd.
+6.23% 1.92B
VELOXIS PHARMACEUTICALS A/S Stock Veloxis Pharmaceuticals A/S
-0.50% 1.64B
Specialty & Advanced Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 300558 Stock